Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 4, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

The intermediate-risk gap in AI-based breast cancer stratification

Filippos Koinis1, Emmanouil Saloustros1, Athanasios Kotsakis1

  • 1Laboratory of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, GR-41110 Larissa, Greece; Department of Medical Oncology, University General Hospital of Larissa, Larissa, Greece.

The Lancet. Oncology
|June 29, 2026
PubMed
Summary

No abstract available in PubMed .

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Related Experiment Videos

Last Updated: Jul 4, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterizing Gynecological Cancers with the Uncommon dMMR/MSS Phenotype in Lynch Syndrome Patients.

Journal of clinical medicine·2026
Same author

Epidemiological trends of non-small cell lung cancer and systemic treatment rates as part of initial therapeutic strategy from 2016 to 2020 in Greece: results of the epidemiological part of INFINITY study.

BMC cancer·2026
Same author

When Not to Push the Boulder.

JAMA oncology·2026
Same author

<i>AXL</i>-mRNA Overexpression in Size-Based Enriched Circulating Tumor Cells as a Potential Biomarker for Anti-AXL Targeted Therapies in Non-Small-Cell Lung Cancer.

Cancers·2026
Same author

Repurposing Artesunate to Combat Progression and Metastasis via Targeting Circulating Tumor Cells.

Oncology research·2026
Same author

Fibroblast Activation Protein Inhibitor (FAPI) PET: A Scoping Review of Emerging Oncologic and Fibroinflammatory Applications.

Diagnostics (Basel, Switzerland)·2026